

Health and Social Care Committee

Inquiry into access to medical technologies: summary of additional information

<b>Witness name/ organisation</b>	<b>Request</b>	<b>Response</b>
Karen Samuels, All Wales Medicines Strategy Group	Ms Samuels noted that the Welsh Analytical Prescribing Support Unit has been monitoring the usage of medicines appraised by AWMSC and NICE, and agreed to share the paper outlining the results of this monitoring with the Committee.	A copy of the paper can be viewed <a href="#">here</a> . (MT – AI1 on website).
Dr Phil Webb, Welsh Health Specialised Services Committee (WHSSC)	Dr Webb agreed to provide a note to the Committee outlining one key recommendation that WHSSC would make to the Committee in relation to improving access to medical technologies in Wales and how this could be achieved.	A copy of the note can be viewed <a href="#">here</a> . (MT – AI2 on website).
Emma Greenwood, Cancer Research UK	Emma Greenwood informed the Committee of recent work undertaken in collaboration between Cancer Research UK and NHS England which asked relevant industry groups how they envisaged the field of radiography in 10 years. Ms Greenwood agreed to share information on this work with the Committee.	A copy of this work can be viewed <a href="#">here</a> . (MT – AI3 on website).

<p>Buddug Cope, Genetic Alliance UK</p>	<p>Buddug Cope agreed to provide the Committee with information regarding the link between the NICE health technology programme and the UK Genetic Testing Network (UKGTN).</p> <p>Ms Cope also agreed to provide the Committee with further clarification regarding the relationship between the approval of new tests by UKGTN and their subsequent commissioning by NHS Scotland.</p>	<p>A copy of the response can be viewed <a href="#">here</a>. (MT – AI4 on website).</p>
<p>Lars Sundstrom, West of England Academic Health Science Network</p>	<p>Lars Sundstrom, West of England Academic Health Science Network, agreed to provide a note on the new system that has been introduced in England (that is available to Welsh organisations) which allows access to funds and provides a method of commissioning research and development through the healthcare system.</p>	<p>An overview of the system can be found <a href="#">here</a>. (MT – AI5 on website).</p>
<p>Dr Nazia Hussain, Royal College of General Practitioners</p>	<p>Dr Nazia Hussain indicated that she would provide:</p> <ul style="list-style-type: none"> <li>- a note on how the Royal College of General Practitioners considers the voice of patients in developing its approaches to technologies and innovation, and how the College believes the voice of patients</li> </ul>	<p>A copy of the information can be found <a href="#">here</a>. (MT – AI6 on website).</p>

	<p>should be considered in the appraisal and commissioning process;</p> <ul style="list-style-type: none"><li>- a note clarifying whether the use of medical technologies does or will form part of the revalidation process for GPs.</li></ul>	
--	---	--